ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 173 filers reported holding ASCENDIS PHARMA A/S in Q2 2021. The put-call ratio across all filers is 4.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,064 | +32.5% | 11,367 | +26.3% | 0.01% | +50.0% |
| Q2 2023 | $803 | -11.9% | 9,000 | +5.9% | 0.00% | -20.0% |
| Q1 2023 | $911 | +5.1% | 8,500 | +19.7% | 0.01% | 0.0% |
| Q4 2022 | $867 | -99.9% | 7,100 | -26.0% | 0.01% | -28.6% |
| Q3 2022 | $991,000 | +11.1% | 9,600 | 0.0% | 0.01% | +16.7% |
| Q2 2022 | $892,000 | -21.6% | 9,600 | -1.0% | 0.01% | 0.0% |
| Q1 2022 | $1,138,000 | -12.8% | 9,700 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $1,305,000 | -22.8% | 9,700 | -8.5% | 0.01% | -33.3% |
| Q3 2021 | $1,690,000 | +38.2% | 10,600 | +14.0% | 0.01% | +50.0% |
| Q2 2021 | $1,223,000 | +2.0% | 9,300 | 0.0% | 0.01% | -14.3% |
| Q1 2021 | $1,199,000 | -30.2% | 9,300 | -9.7% | 0.01% | -30.0% |
| Q4 2020 | $1,718,000 | +27.9% | 10,300 | +18.4% | 0.01% | 0.0% |
| Q3 2020 | $1,343,000 | -47.8% | 8,700 | -50.0% | 0.01% | -9.1% |
| Q2 2020 | $2,574,000 | – | 17,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
| RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
| Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
| BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
| Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
| Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
| Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
| Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
| Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
| Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |